Semaglutide selectively activates the GLP-1 receptor, producing: Glucose-dependent insulin secretion : Reduces hypoglycemia risk compared to non-incretin agents Glucagon suppression : Reduces hepatic glucose output in the hyperglycemic state Gastric emptying delay : Contributes to postprandial glucose control and satiety Central appetite regulation : Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and alter food preferences The simplicity of semaglutide's single-receptor mechanism is both a limitation (no energy expenditure enhancement from glucagon) and a strength (thoroughly understood pharmacology, predictable effects, extensive safety characterization)
doi: 10.1016/S0950-3579(05)80113-X 51 AthanassakisIMouratidouMSakkaPEvangeliouASpiliotiMVassiliadisS
The insurer will give its largest segment of customers, employers with 100 workers or more, the option of retaining coverage of the drugs for weight loss by paying an extra charge in their health plans
Ready to explore your weight loss options
So all in all, Hims & Hers is performing well so far in 2024 even when removing the hyper-scaling obesity segment
Ozempic (semaglutide), a GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK, lists dizziness as an uncommon side effect in the MHRA-approved Summary of Product Characteristics
